Trial | NCT02796183  Report issue

Official Title

The Efficacy of Subconjunctival Bevacizumab in Diabetic Macular Edema

  • Phase

    N/A

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Intervention/Treatment

    bevacizumab ...

  • Study Participants

    20
This study evaluates the effects of subconjunctivally injected bevacizumab in patients with diffuse diabetic macular edema.
At baseline, the macular thicknesses of both eyes of the patients with persistant diabetic macular edema were measured by optical coherence tomography. After 3.75mg bevacizumab was injected into subconjunctival space of the eyes with diabetic macular edema. The measurements of the macular thicknesses were repeated by optical coherence tomography in 15th, 30th, 60th day after injections. The macular thickness measurements before and after injection were compared.
Study Started
Jan 31
2015
Primary Completion
Apr 30
2016
Study Completion
May 31
2016
Last Update
Jun 10
2016
Estimate

Drug Subconjunctival bevacizumab (Altuzan)

Subconjunctival injections of Altuzan 3.75mg were applied in order to eliminate the macular edema.

Diabetic macular edema Other

Bevacizumab (Altuzan) was injected subconjunctival space of the patients.

Criteria 

Inclusion Criteria:

Having diffuse diabetic macular edema persisted at least 1 month
No intravitreal injection in last 3 months.
No retinal laser photocoagulation in last 6 months
Not have any other macular disease causing macular edema

Exclusion Criteria:

Having ischemic macula
Intravitreal injection in last 3 months.
Retinal laser photocoagulation in last 6 months
Have any other macular disease causing macular edema
No Results Posted